Upgrade to SI Premium - Free Trial

Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)

October 9, 2026 7:05 AM
Canaccord analyst Sumant Kulkarni reiterated a Buy rating and $21.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst commented: "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments